Boston Scientific Corporation reported net sales of $5.061 billion for the second quarter of 2025, reflecting a growth of 22.8% compared to the same period last year. The company achieved a GAAP net income of $797 million, or $0.53 per share, up from $324 million, or $0.22 per share, in the prior year. Adjusted earnings per share (EPS) were $0.75, exceeding prior guidance. The company noted significant sales growth in its MedSurg and Cardiovascular segments and across various regions, particularly in the U.S., which saw a 30.7% increase in reported sales. Additionally, Boston Scientific received FDA approval for new medical devices and completed several acquisitions to enhance its product offerings.
For the full year 2025, Boston Scientific anticipates net sales growth of approximately 18% to 19% on a reported basis and adjusted EPS in the range of $2.95 to $2.99. The company's guidance for the third quarter includes a projected EPS of $0.44 to $0.46 on a GAAP basis and adjusted EPS of $0.70 to $0.72. The company continues to focus on expanding its product portfolio and investing in clinical trials to drive future growth.
linkJul 23, 2025 06:32:54
Boston Scientific Corporation announced net sales of $4.561 billion for the fourth quarter of 2024, marking a 22.4 percent increase compared to the same period last year. The company also reported a GAAP net income of $566 million, or $0.38 per share, up from $504 million or $0.34 per share a year earlier. Adjusted earnings per share rose to $0.70 from $0.55 in the previous year. Sales growth was driven by strong performance in the Cardiovascular segment, which saw a reported increase of 28.8 percent, and a notable 30.7 percent growth in the U.S. market. Additionally, the company completed several strategic acquisitions and received regulatory approvals for new products, enhancing its market position and product offerings.
Conversely, the company's GAAP net income per share fell short of its guidance range of $0.41 to $0.43. The MedSurg segment experienced slower growth, with only a 12.4 percent increase reported. Furthermore, while the overall sales growth was significant, the company faced challenges in achieving its organic sales growth targets, which were below expectations. The financial results highlighted the impact of foreign currency fluctuations and the complexities involved in integrating new acquisitions, which may influence future performance.
linkFeb 05, 2025 06:41:47
Boston Scientific Corporation has reached a settlement in a shareholder derivative action, which includes adopting corporate governance reforms aimed at addressing allegations made in the case. The settlement is considered beneficial for the company and its shareholders, as it aims to resolve ongoing legal disputes and associated costs, while also enhancing governance practices within the organization.
On the downside, the settlement follows claims of wrongdoing against several executives, including allegations of breaches of fiduciary duty and misleading statements that inflated stock prices. While the defendants deny any wrongdoing, the legal proceedings and associated costs have raised concerns regarding the company's management and governance practices, leading to the necessity for reform measures as part of the settlement agreement.
linkJan 16, 2025 16:26:10
Boston Scientific has elected David Habiger to its board, bringing over 30 years of leadership experience, particularly in technology. His background includes roles at J.D. Power and other tech firms. The company’s CEO expressed enthusiasm for Habiger's insights to enhance their innovative medical solutions, signaling positive growth potential.
linkJul 30, 2024 16:18:24
Boston Scientific saw impressive growth in Q2 2024, with net sales reaching $4.12 billion, a 14.5% increase from last year. Their earnings per share also rose from $0.18 to $0.22. However, EPS fell short of expectations, which were between $0.35 and $0.37. The company received regulatory approval for new products and announced plans to acquire Silk Road Medical, signaling confidence in future growth.
linkJul 24, 2024 06:35:23
Boston Scientific's Q1 2024 net sales reached $3.856 billion, showing growth in all segments and regions. The company's GAAP net income and adjusted EPS also improved significantly compared to the previous year. Key achievements include the launch of FARAPULSE Pulsed Field Ablation System and FDA approvals for innovative medical devices. Strategic collaborations and financial activities like Senior Notes offering were highlighted. The company's 2024 full-year net sales growth is estimated to be around 11-13 percent, showcasing a positive outlook.
linkApr 24, 2024 06:34:09
Boston Scientific Corporation priced €2.0 billion senior notes through its finance subsidiary. The notes, due in 2029 and 2032, will be guaranteed by the company. The proceeds will fund the acquisition of Axonics, Inc., repay existing debts, and cover general corporate purposes. The offering is set to close on February 27, 2024. Boston Scientific is a global leader in medical technologies, catering to various health conditions and diseases for over 40 years.
linkFeb 27, 2024 16:37:36
Boston Scientific Corporation announced a 14.9% increase in net sales for Q4 2023, with GAAP net income of $504 million. Full year 2023 net sales grew by 12.3%, with GAAP net income of $1.570 billion. The company achieved net sales growth in all reportable segments and regions. Notable recent developments include FDA approvals and clinical trial enrollments. Additionally, the company completed an acquisition and announced an agreement to acquire another company.
linkJan 31, 2024 06:32:20
Boston Scientific Corporation reported net sales of $3.527 billion during the third quarter of 2023, growing 11.2 percent on a reported basis, 11.1 percent on an operational basis, and 10.2 percent on an organic basis compared to the prior year period. The company also reported GAAP net income of $505 million or $0.34 per share, compared to $174 million or $0.12 per share a year ago, and achieved adjusted EPS of $0.50 for the period. Boston Scientific announced positive results from clinical trials, FDA approvals for various medical devices, and an agreement to acquire Relievant Medsystems, Inc.
linkOct 26, 2023 06:36:04